Is EEYMF or ABBV a better dividend investment in 2026?

EEYMF currently yields 20000.00% with a 5% 5-year dividend growth rate. ABBV yields 3.12% with 8.9% growth. The better choice depends on your goal: EEYMF offers higher current income.

What is the dividend yield difference between EEYMF and ABBV?

EEYMF has a forward dividend yield of 20000.00% ($2.00/share annually). ABBV yields 3.12% ($6.65/share annually). The yield gap is 19996.88 percentage points.

Home › Compare › EEYMF vs ABBV

EEYMF vs ABBV: Dividend Comparison 2026

EEYMF yields 20000.00% · ABBV yields 3.12%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 EEYMF wins by $52481917574412746752.00M in total portfolio value

INVESTMENT

TIME HORIZON10 years

EEYMF

● Live price

20000.00%

Share price

$0.01

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$52481917574412746752.00M

Annual income

$51,970,745,957,167,775,000,000,000.00

Full EEYMF calculator →

ABBV

AbbVie Inc.

● Live price

3.12%

Share price

$213.22

Annual div

$6.65

5Y div CAGR

40.6%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$104.7K

Annual income

$25,725.73

Full ABBV calculator →

Portfolio growth — EEYMF vs ABBV

📍 EEYMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	EEYMF	ABBV
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, EEYMF + ABBV cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

EEYMF pays

ABBV pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EEYMF

Annual income on $10K today (after 15% tax)

$1,700,000.00/yr

After 10yr DRIP, annual income (after tax)

$44,175,134,063,592,610,000,000,000.00/yr

ABBV

Annual income on $10K today (after 15% tax)

$265.10/yr

After 10yr DRIP, annual income (after tax)

$21,866.87/yr

At 15% tax rate, EEYMF beats the other by $44,175,134,063,592,610,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EEYMF + ABBV for your $10,000?

EEYMF: 50%ABBV: 50%

100% ABBV50/50100% EEYMF

Portfolio after 10yr

$26240958787206373376.00M

Annual income

$25,985,372,978,583,888,000,000,000.00/yr

Blended yield

99.03%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

EEYMF

No analyst data

Altman Z

0.8

Piotroski

4/9

ABBV

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$256.15

+20.1% upside vs current

Range: $223.00 — $299.00

Altman Z

2.0

Piotroski

8/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EEYMF buys

ABBV buys

No recent congressional trades found for EEYMF or ABBV in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricEEYMFABBV

Forward yield	20000.00% ✓	3.12%
Annual dividend / share	$2.00	$6.65 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	40.6% ✓
Portfolio after 10y	$52481917574412746752.00M ✓	$104.7K
Annual income after 10y	$51,970,745,957,167,775,000,000,000.00 ✓	$25,725.73
Total dividends collected	$52448189483771600896.00M ✓	$63.0K
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: EEYMF vs ABBV ($10,000, DRIP)

Year	EEYMF Portfolio	EEYMF Income/yr	ABBV Portfolio	ABBV Income/yr	Gap
1← crossover	$2,010,700	$2,000,000.00	$11,559	$438.51	+$2.00M → EEYMF
2	$377,983,225	$375,831,775.70	$13,494	$640.86	+$377.97M → EEYMF
3	$66,433,479,469	$66,029,037,418.28	$15,951	$945.97	+$66433.46M → EEYMF
4	$10,916,985,471,987	$10,845,901,648,955.73	$19,152	$1,413.89	+$10916985.45M → EEYMF
5	$1,677,384,363,769,318	$1,665,703,189,314,291.80	$23,443	$2,146.38	+$1677384363.75M → EEYMF
6	$240,985,175,079,139,100	$239,190,373,809,905,920.00	$29,391	$3,321.96	+$240985175079.11M → EEYMF
7	$32,373,573,631,143,694,000	$32,115,719,493,809,017,000.00	$37,948	$5,265.87	+$32373573631143.66M → EEYMF
8	$4,066,766,648,320,630,000,000	$4,032,126,924,535,306,000,000.00	$50,795	$8,596.74	+$4066766648320630.00M → EEYMF
9	$477,730,483,406,513,300,000,000	$473,379,043,092,810,300,000,000.00	$71,034	$14,549.41	+$477730483406513344.00M → EEYMF
10	$52,481,917,574,412,750,000,000,000	$51,970,745,957,167,775,000,000,000.00	$104,715	$25,725.73	+$52481917574412746752.00M → EEYMF

EEYMF vs ABBV: Complete Analysis 2026

EEYMF — Stock

Firefinch Limited operates as a gold mining company. It has an 80% interest in the Morila Gold Mine in Mali. The company was formerly known as Mali Lithium Limited and changed its name to Firefinch Limited in November 2020. Firefinch Limited was incorporated in 2005 and is based in West Perth, Australia.

Full EEYMF Calculator →

ABBV — Healthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →

📬

Get this EEYMF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EEYMF vs SCHD EEYMF vs JEPI EEYMF vs O EEYMF vs KO EEYMF vs MAIN EEYMF vs JNJ EEYMF vs MRK EEYMF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.